Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/28—Halogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/30—Hetero atoms other than halogen
  • C07D333/36—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
  • C07D333/44—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms attached in position 5
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

• the invention relates to substituted 3- (BenzoyIureido) thiophene derivatives and their physiologically acceptable salts and physiologically functional derivatives.
• EP 0 300 972 describes benzoylureido-thiophenes having pesticidal, especially insecticidal and acaricidal activity.
• the object of the invention was to provide compounds with which a prevention and treatment of diabetes mellitus is possible.
• the compounds should especially develop a therapeutically useful blood sugar lowering effect.
• the invention therefore relates to compounds of the formula I,
• R5 is F, Cl or Br
• R1 H, F, Cl, Br;
• R 2 is H, F, Cl, Br, (CC 6 ) alkyl, CF 3 , OCF 3 , NO 2 , CN, O- (dC 6 ) alkyl, CO (C
• C 6 ) -alkyl COOH, COO (C 1 -C 6 ) -alkyi, CONH 2 , CONH (CC 6 ) -alkyl, CON ((CC 6 ) -alkyl) 2 , SO 2 - (dC 6 ) -alkyl , or the rest A;
• R 3 is H, (CC 6 ) -alkyl, COO (CC 6 ) -alkyl, SO 2 (C 1 -C 6 ) -alkyl, (C 1 -C 6 ) -alkyl
• R 4 is H, (C 1 -C 6 ) -alkyl, COO (C 1 -C 6 ) -alkyl, SO 2 - (CC 6 ) -alkyl, SO 2 -pipridinyl,
• A is a heterocyclic radical of formula 2a, 2b, 2c or 3;
• X is O or NH
• Y is OH or NH 2 ;
• Z is OH, O (dC 6 ) alkyl, NH 2 , NH CrCeJ alkyl, N ((CC 6 ) alkyl) 2 ;
• R5 is F, Cl or Br
• R 2 is H, F, Cl, Br, (C 1 -C 6 ) -alkyl, CF 3 , OCF 3 , NO 2 , CN, O- (C 1 -C 6 ) -alkyl, CO (C 1 -C 6 ) -alkyl, COOH, COO ( dC 6 ) -alkyl, CONH 2 , CONH (dC 6 ) -alkyl, CON ((C 1 -C 6 ) -alkyl) 2 , SO 2 - (C 1 -C 6 ) -alkyl, or the radical A;
• R 3 is H, (C 1 -C 6 ) -alkyl, COO (CC 6 ) -alkyl, SO 2 (C 1 -C 6 ) -alkyl, (CC 6 ) -alkyl-phenyl, phenyl, SO 2 -phenyl, where the phenyl ring is in each case up to twice may be substituted by F or Cl;
• R 4 is H, (CC 6 ) -alkyl, COO (dC 6 ) -alkyl, SO 2 - (dC 6 ) -alkyl, SO 2 -pipridinyl, SO 2 -piperazinyl, (C 1 -C 6 ) -alkyl-phenyl, wherein the phenyl ring , the piperidinyl ring and the piperazinyl ring up to two times with F, Cl, CN, OH, (dC 6 ) alkyl, O- (CC 6 ) alkyl, CF 3 , OCF 3 , COOH, COO (CC 6 ) alkyl or CONH 2 may be substituted;
• X is O or NH
• Y is OH or NH 2 ;
• R 2 COOH, COO (C 1 -C 6 ) -alkyl, CONH 2 , CONH (C 1 -C 6 ) -alkyl, CON (C 1 -C 6 ) -
• R 3 is H, (CC 6 ) -alkyl, COO (CC 6 ) -alkyl, SO 2 (C 1 -C 6 ) -alkyl, (C 1 -C 6 ) -alkyl
• R 4 is H, (CC 6 ) -alkyl, COO (C 1 -C 6 ) -alkyl, SO 2 - (C 1 -C 6 ) -alkyl, SO 2 -pipridinyl,
• A is a heterocyclic radical of formula 2a or 2b;
• X is O or NH
• Y is OH or NH 2 ; and their physiologically acceptable salts.
• the invention relates to compounds of the formula I, in the form of their racemates, racemic mixtures and pure enantiomers, and to their diastereomers and mixtures thereof.
• alkyl radicals in the substituents R2, R3 and R4 can be both straight-chain and branched.
• radicals or substituents can occur several times in the compounds of the formula I, for example A, they may all, independently of one another, have the meanings indicated and be identical or different.
• Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention are salts of inorganic acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric and organic acids, e.g.
• Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts), alkaline earth salts (such as magnesium and calcium salts), trometamol (2-amino-2-hydroxymethyl-1, 3-propanediol), diethanolamine, lysine, or ethylenediamine.
• Salts with a non-pharmaceutically acceptable anion, such as Trifluoroacetate are also within the scope of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and / or for use in non-therapeutic, for example, in vitro applications.
• physiologically functional derivative refers to any physiologically acceptable derivative of a compound of formula I, e.g. an ester which, when administered to a mammal, such as human, is capable of (directly or indirectly) forming a compound of formula I or an active metabolite thereof.
• the physiologically functional derivatives also include prodrugs of the compounds according to the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may or may not be effective.
• the compounds of the invention may also be in various polymorphic forms, e.g. as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds of the invention are within the scope of the invention and are a further aspect of the invention.
• aryl radical is understood as meaning a phenyl, naphthyl, biphenyl, tetrahydronaphthyl, alpha- or beta-tetralonic, indanyl or indan-1-onyl radical.
• heterocyclic ring and “heterocyclic radical” as used herein refer to heteroaryl radicals and heterocycloalkyl radicals derived from 3 to 10 membered carbon rings in which one or more carbon atoms are replaced by one or more atoms selected from the group consisting of oxygen, sulfur and nitrogen.
• Suitable "heterocyclic rings” or “heterocyclic radicals” are acridines! Azocinyl, benzimidazolyl, benzofuryl, benzothienyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolybenzimidazalinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H quinolizinyl, quinoxalinyl, quinuclidinyl ,.
• Pyridyl is both 2-, 3- and 4-pyridyl.
• Thienyl is both 2- and 3-thienyl.
• Furyl is both 2- and 3-furyl.
• N-oxides of these compounds e.g. 1- Oxy-2-, 3- or 4-pyridyl.
• the compound (s) of the formula (I) may also be used in combination with further active ingredient be administered.
• the amount of a compound of Formula I required to achieve the desired biological effect is dependent upon a number of factors, e.g. the selected specific compound, the intended use, the mode of administration and the clinical condition of the patient.
• the daily dose is in the range of 0.3 mg to 100 mg (typically 3 mg and 50 mg) per day per kilogram of body weight, e.g. 3-10 mg / kg / day.
• An intravenous dose may e.g. in the range of 0.3 mg to 1.0 mg / kg, which can be suitably administered as an infusion of 10 ng to 100 ng per kilogram per minute.
• Suitable infusion solutions for these purposes may e.g. from 0.1 ng to 10 mg, typically from 1 ng to 10 mg per milliliter.
• Single doses may e.g. from 1 mg to 10 g of the active ingredient.
• injectable ampoules of from 1 mg to 100 mg, and orally administrable unit dose formulations such as tablets or capsules may contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg.
• the compounds according to formula I can themselves be used as compound, but they are preferably present with a compatible carrier in the form of a pharmaceutical composition.
• the carrier must of course be compatible in the sense that it is compatible with the other ingredients of the composition and is not harmful to the patient.
• the carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a single dose, for example, as a tablet, which may contain from 0.05% to 95% by weight of the active ingredient.
• Other pharmaceutically active substances may likewise be present, including further compounds of the formula I.
• the pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which essentially consist in mixing the ingredients with pharmacologically acceptable carriers and / or excipients ,
• compositions according to the invention are those for oral, rectal, topical, peroral (eg sublingual) and parenteral (eg subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration in each individual case is the nature and severity of the condition to be treated and the nature of the particular compound used Formula I is dependent.
• coated formulations and coated slow release formulations are within the scope of the invention. Preference is given to acid and enteric formulations. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
• Suitable pharmaceutical compounds for oral administration may be in separate units, such as capsules, cachets, lozenges or tablets, each containing a certain amount of the compound of formula I; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
• these compositions may be prepared by any suitable pharmaceutical method comprising a step of contacting the active ingredient and the carrier (which may consist of one or more additional ingredients).
• the compositions are prepared by uniformly and homogeneously mixing the active ingredient with a liquid and / or finely divided solid carrier, after which the product is molded, if necessary.
• a tablet can be made by compressing or molding a powder or granules of the compound, optionally with one or more additional ingredients.
• Compressed tablets can be prepared by tableting the compound in free-flowing form, such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent and / or surfactant / dispersing agent in a suitable machine.
• Molded tablets may be prepared by shaping the powdered compound moistened with an inert liquid diluent in a suitable machine.
• compositions suitable for peroral (sublingual) administration include lozenges containing a compound of Formula I with a flavor, usually sucrose and gum arabic or tragacanth, and lozenges containing the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
• Suitable pharmaceutical compositions for parenteral administration preferably comprise sterile aqueous preparations of a compound according to formula I which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although the administration may also be subcutaneous, intramuscular or intradermal as an injection. These preparations may preferably be prepared by mixing the compound with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions of the invention generally contain from 0.1% to 5% by weight of the active compound.
• Suitable pharmaceutical compositions for rectal administration are preferably as single dose suppositories. These can be prepared by mixing a compound according to formula I with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
• Suitable pharmaceutical compositions for. the topical application on the skin are preferably as ointment, cream, lotion, paste, spray, aerosol or oil.
• Vaseline, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances can be used as the carrier.
• the active ingredient is generally present at a level of from 0.1% to 15% by weight of the composition, for example from 0.5% to 2%.
• Suitable pharmaceutical compositions for transdermal applications may be as single patches present, which are suitable for long-term close contact with the epidermis of the patient.
• patches suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and / or dispersed in an adhesive or dispersed in a polymer.
• a suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%.
• the active ingredient can be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 2 (6): 318 (1986).
• active ingredients for the combination preparations are suitable: All Antidiabetika, which are mentioned in the red list 2001, chapter 12. They can be combined with the compounds of the formula I according to the invention in particular for the synergistic effect improvement.
• the administration of the active ingredient combination can be carried out either by separate administration of the active ingredients to the patient or in the form of combination preparations in which several active ingredients are present in a pharmaceutical preparation.
• Most of the drugs listed below are disclosed in USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001.
• Antidiabetics include insulin and insulin derivatives, such as Lantus ® (see www.lantus.com) or HMR 1964 fast-acting insulins (see US 6,221, 633), GLP-1 derivatives such as those described in WO 98/08871 of Novo Nordisk A / S, as well as orally active hypoglycemic agents.
• the orally active hypoglycemic agents preferably include sulphonyl fluorides, biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists,
• Potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 by Novo Nordisk A / S, insulin sensitizers, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and / or glycogenolysis, modulators of glucose uptake lipid metabolizing compounds such as antihyperlipidemic agents and antilipidemic agents, compounds that reduce food intake, PPAR and PXR agonists, and drugs that act on the ATP-dependent potassium channel of beta cells.
• the compounds of formula I are administered in combination with an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin.
• an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin.
• the compounds of formula I are administered in combination with a cholesterol resorption inhibitor, e.g. Ezetimibe, Tiqueside, Pamaqueside.
• a cholesterol resorption inhibitor e.g. Ezetimibe, Tiqueside, Pamaqueside.
• the compounds of formula I are administered in combination with a PPAR gamma agonist, e.g. Rosiglitazone, pioglitazone, JTT-501, Gl 262570.
• a PPAR gamma agonist e.g. Rosiglitazone, pioglitazone, JTT-501, Gl 262570.
• the compounds of formula I in combination with PPAR alpha agonist e.g. GW 9578, GW 7647.
• the compounds of formula I in combination with a mixed PPAR alpha / gamma agonist e.g. GW 1536, AVE 8042, AVE 8134, AVE 0847 or as described in PCT / US 11833, PCT / US 11490, DE10142734.4.
• a mixed PPAR alpha / gamma agonist e.g. GW 1536, AVE 8042, AVE 8134, AVE 0847 or as described in PCT / US 11833, PCT / US 11490, DE10142734.4.
• the compounds of formula I are used in combination with a fibrate, e.g. Fenofibrate, clofibrate, bezafibrate.
• a fibrate e.g. Fenofibrate, clofibrate, bezafibrate.
• the compounds of formula I are administered in combination with an MTP inhibitor, e.g. Implitapide, BMS-201038, R-103757.
• an MTP inhibitor e.g. Implitapide, BMS-201038, R-103757.
• the compounds of the formula I are administered in combination with bile acid resorption inhibitor (see, for example, US Pat. No. 6,245,744 or US Pat. No. 6,221,897), for example HMR 1741.
• the compounds of formula I are administered in combination with a CETP inhibitor, such as JTT-705.
• the compounds of formula I are used in combination with a polymeric bile acid adsorber, e.g. Cholestyramine, colesevelam.
• a polymeric bile acid adsorber e.g. Cholestyramine, colesevelam.
• the compounds of formula I are used in combination with an LDL receptor inducer (see US 6,342,512), e.g. HMR1171, HMR1586.
• the compounds of formula I are administered in combination with an ACAT inhibitor, e.g. Avasimibe, administered.
• an ACAT inhibitor e.g. Avasimibe
• the compounds of formula I are used in combination with an antioxidant, e.g. OPC-14117 administered.
• the compounds of formula I are used in combination with a lipoprotein lipase inhibitor, e.g. NO-1886, administered.
• a lipoprotein lipase inhibitor e.g. NO-1886
• the compounds of formula I are used in combination with an ATP citrate lyase inhibitor, e.g. SB-204990 administered.
• the compounds of formula I are administered in combination with a squalene synthetase inhibitor, e.g. BMS-188494.
• a squalene synthetase inhibitor e.g. BMS-188494.
• the compounds of formula I are administered in combination with a lipoprotein (a) antagonist, such as CI-1027 or nicotinic acid. In one embodiment of the invention, the compounds of formula I are administered in combination with a lipase inhibitor, such as orlistat.
• a lipoprotein (a) antagonist such as CI-1027 or nicotinic acid.
• a lipase inhibitor such as orlistat.
• the compounds of formula I are used in combination with a sulphonylurea such as e.g. Tolbutamide, glibenclamide, glipizide or glimepiride.
• a sulphonylurea such as e.g. Tolbutamide, glibenclamide, glipizide or glimepiride.
• the compounds of formula I are used in combination with a biguanide, e.g. Metformin, administered.
• a biguanide e.g. Metformin
• the compounds of formula I are used in combination with a thiazolidinedione, e.g. Troglitazone, ciglitazone, pioglitazone, rosiglitazone or those described in WO 97/41097 by Dr. med. Reddy's Research Foundation disclosed compounds, particularly 5 - [[4 - [(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy) phenyl] methyl] -2,4-thiazolidinedione.
• the compounds of formula I are administered in combination with a glucosidase inhibitor, e.g. Miglitol or acarbose, administered.
• a glucosidase inhibitor e.g. Miglitol or acarbose
• the compounds of formula I are administered in combination with an agent which acts on the ATP-dependent potassium channel of the beta cells, e.g. Tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
• an agent which acts on the ATP-dependent potassium channel of the beta cells e.g. Tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
• the compounds of formula I are used in combination with more than one of the aforementioned compounds, e.g. in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose,
• the compounds of the formula I are administered in combination with CART modulators (see “cocaine-amphetamine-regulated transcriptinfluenza-metabolism, anxiety and gastric emptying in mice”).
• CART modulators see “cocaine-amphetamine-regulated transcriptinfluenza-metabolism, anxiety and gastric emptying in mice”).
• CART modulators see “cocaine-amphetamine-regulated transcriptinfluenza-metabolism, anxiety and gastric emptying in mice”).
• CART modulators see “cocaine-amphetamine-regulated transcriptinfluenza-metabolism, anxiety and gastric emptying in mice”).
• NPY antagonists eg naphthalene-1-sulfonic acid ⁇ 4 - [(4-amino-quinazoline) 2-ylamino) - methyl] -cyclohexylmethyl ⁇ -amide hydrochloride (CGP 71683A)
• MC4 agonists eg, 1-amin
• the further active ingredient is leptin; see, e.g. "Perspectives in the therapeutic use of leptin", Salvador, Javier; Gomez-
• the further active ingredient is dexamphatamine or
• the other active ingredient is fenfluramine or dexfenfluramine.
• the other active ingredient is sibutramine.
• the other active ingredient is orlistat.
• the other active ingredient is mazindol or phentermine.
• the compounds of formula I in combination with bulking agents preferably insoluble bulking agents
• bulking agents preferably insoluble bulking agents
• Caromax is a carob-containing product of the company Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark availability, 65926 Frankfurt / Main)) administered.
• Combination with Caromax ® is possible in one preparation or by separate administration of compounds of the formula I and Caromax ®.
• Caromax ® can also be administered in the form of food, such as in baked goods or muesli bars.
• the effect of compounds on the activity of the active form of glycogen phosphorylase (GPa) was measured in the reverse direction by following the glycogen synthesis from glucose-1-phosphate by determination of the release of inorganic phosphate. All reactions were performed as duplicates in 96-well microtiter plates (Costar # 3696), the change in absorbance due to the formation of the reaction product at the wavelength specified below in a Multiskan Ascent Elisa Reader (Lab Systems. Finland). In order to measure the GPa enzyme activity in the reverse direction, the conversion of glucose-1-phosphate to glycogen and inorganic phosphate was determined by the general method of Engers et al.
• Human glycogen phosphorylase a (for example with 0.76 mg protein / ml (Aventis Pharma GmbH) , dissolved in buffer solution E (25 mM R-glycerophosphate, pH 7.0, 1 mM EDTA and 1 mM dithiotreitol) was treated with buffer T (50 M Hepes, pH 7.0, 100 mM KCl, 2.5 mM EDTA, 2 , 5 mM MgCl 2 6H 2 O) and supplemented with 5 mg / ml glycogen to a concentration of 10 ug protein / ml.
• buffer solution E 25 mM R-glycerophosphate, pH 7.0, 1 mM EDTA and 1 mM dithiotreitol
• buffer T 50 M Hepes, pH 7.0, 100 mM KCl, 2.5 mM EDTA, 2 , 5 mM MgCl 2 6H 2 O
• Test substances were prepared as 10 mM solution in DMSO and diluted to 50 uM with buffer solution T. to 10 microliters of this Solution were 10 ul 37.5 mM glucose dissolved in buffer solution T and 5 mg / ml glycogen, and 10 .mu.l of a solution of human glycogen phosphorylase a (10 ug protein / ml) and 20 ul glucose-1-phosphate, 2.5 mM
• the basal level of glycogen phosphorylase a activity in the absence of test substance was determined by adding 10 ⁇ l of buffer solution T (0.1% DMSO) g became 40 Incubated at room temperature and "the liberated inorganic phosphate by the general method of Drueckes et al.
• Example 1 a) 3- (tert-Butoxycarbonylamino) -thiophene-2-carboxylic acid hydrazide
• Example 2 a) 2- (5-Amino- [1,3,4] oxdiazol-2-yl) -thiophen-3-yl] -carbamic acid tert-butyl ester
• Example 4 a) 1- (5-Chloro-4-nitro-thiophene-2-sulfonyl) -piperidine and 1- (5-piperidino-4-nitro-thiophene-2-sulfonyl) -piperidine
• Example 36 a) 5- (4-Fluoro-phenyl) -2- (1H-tetrazol-5-yl) -thiophen-3-ylamine
• the compounds of the formula I can be prepared by reacting ureas of the formula 5 or 3-aminothiophene derivatives of the formula 6 with benzoic acid derivatives the formula 4,
• R1 to R5 have the meanings given above and X1 may be equal to Cl or NCO, with acid chlorides or anhydrides or benzoyl isocyanates, implemented.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=32841675

Family Applications (1)

Country Status (21)

Cited By (6)

Families Citing this family (1)

Citations (3)

Family Cites Families (8)

• 2003
  • 2003-02-17 DE DE10306502A patent/DE10306502B4/de not_active Expired - Fee Related
• 2004
  • 2004-02-04 HR HR20050715A patent/HRP20050715A2/xx not_active Application Discontinuation
  • 2004-02-04 KR KR1020057015029A patent/KR20050105470A/ko not_active Withdrawn
  • 2004-02-04 CN CNA2004800044004A patent/CN1751036A/zh active Pending
  • 2004-02-04 MX MXPA05008331A patent/MXPA05008331A/es not_active Application Discontinuation
  • 2004-02-04 RU RU2005129109/04A patent/RU2005129109A/ru not_active Application Discontinuation
  • 2004-02-04 JP JP2006501724A patent/JP4589301B2/ja not_active Expired - Fee Related
  • 2004-02-04 CA CA002516269A patent/CA2516269A1/en not_active Abandoned
  • 2004-02-04 PL PL376753A patent/PL376753A1/pl not_active Application Discontinuation
  • 2004-02-04 EP EP04707896A patent/EP1597247B1/de not_active Expired - Lifetime
  • 2004-02-04 DE DE502004007668T patent/DE502004007668D1/de not_active Expired - Lifetime
  • 2004-02-04 WO PCT/EP2004/000993 patent/WO2004072060A1/de not_active Ceased
  • 2004-02-04 AT AT04707896T patent/ATE402160T1/de not_active IP Right Cessation
  • 2004-02-04 AU AU2004212054A patent/AU2004212054A1/en not_active Abandoned
  • 2004-02-04 BR BRPI0407552-8A patent/BRPI0407552A/pt not_active IP Right Cessation
  • 2004-02-13 TW TW093103411A patent/TW200505892A/zh unknown
  • 2004-02-13 AR ARP040100457A patent/AR043179A1/es unknown
  • 2004-02-17 PE PE2004000163A patent/PE20050221A1/es not_active Application Discontinuation
• 2005
  • 2005-07-07 ZA ZA200505487A patent/ZA200505487B/en unknown
  • 2005-08-12 CO CO05080324A patent/CO5690549A2/es not_active Application Discontinuation
  • 2005-08-16 MA MA28443A patent/MA27657A1/fr unknown
  • 2005-09-07 NO NO20054168A patent/NO20054168L/no unknown

Patent Citations (3)

Also Published As

Similar Documents

Legal Events